Marinus Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, MRNS, Marinus Pharmaceuticals Inc, priceseries

Marinus Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
7.34
Close
7.39
High
7.58
Low
7.34
Previous Close
7.35
Daily Price Gain
0.04
YTD High
13.15
YTD High Date
Jan 3, 2022
YTD Low
7.20
YTD Low Date
Mar 4, 2022
YTD Price Change
-5.65
YTD Gain
-43.33%
52 Week High
20.04
52 Week High Date
Mar 10, 2021
52 Week Low
7.20
52 Week Low Date
Mar 4, 2022
52 Week Price Change
-9.33
52 Week Gain
-55.80%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 13. 2017
5.00
Feb 22. 2017
5.42
6 Trading Days
8.40%
Link
LONG
Mar 6. 2017
5.48
Mar 20. 2017
6.14
10 Trading Days
12.13%
Link
LONG
Jul 14. 2017
5.68
Aug 1. 2017
7.01
12 Trading Days
23.43%
Link
LONG
Aug 9. 2017
9.04
Oct 9. 2017
24.45
42 Trading Days
170.45%
Link
LONG
Oct 27. 2017
23.96
Oct 30. 2017
25.18
1 Trading Days
5.09%
Link
LONG
Nov 1. 2017
23.16
Nov 14. 2017
26.14
9 Trading Days
12.86%
Link
LONG
Dec 13. 2017
32.32
Dec 15. 2017
35.06
2 Trading Days
8.48%
Link
LONG
Apr 9. 2018
17.00
Apr 23. 2018
18.89
10 Trading Days
11.12%
Link
LONG
May 21. 2018
19.20
Jun 18. 2018
27.39
19 Trading Days
42.66%
Link
LONG
Aug 27. 2018
24.76
Sep 10. 2018
26.23
9 Trading Days
5.93%
Link
LONG
Sep 13. 2018
27.16
Oct 1. 2018
33.61
12 Trading Days
23.75%
Link
LONG
Nov 29. 2018
18.48
Dec 4. 2018
19.52
3 Trading Days
5.63%
Link
LONG
Jan 3. 2019
12.44
Jan 14. 2019
13.40
7 Trading Days
7.74%
Link
LONG
Jan 31. 2019
13.28
Feb 7. 2019
14.05
5 Trading Days
5.82%
Link
LONG
Mar 28. 2019
15.76
Apr 12. 2019
16.98
11 Trading Days
7.73%
Link
LONG
Apr 23. 2019
17.20
May 1. 2019
18.10
6 Trading Days
5.23%
Link
LONG
Sep 3. 2019
5.08
Sep 18. 2019
6.37
11 Trading Days
25.31%
Link
LONG
May 15. 2020
9.12
May 28. 2020
11.21
8 Trading Days
22.90%
Link
LONG
Sep 10. 2020
7.80
Sep 24. 2020
11.03
10 Trading Days
41.38%
Link
LONG
May 20. 2021
15.34
Jun 3. 2021
16.62
9 Trading Days
8.38%
Link
LONG
Oct 28. 2021
11.49
Nov 17. 2021
12.47
14 Trading Days
8.50%
Link
LONG
Dec 21. 2021
11.23
Jan 5. 2022
11.81
10 Trading Days
5.19%
Link
LONG
Feb 4. 2022
10.40
Feb 17. 2022
11.42
9 Trading Days
9.76%
Link
Company Information
Stock Symbol
MRNS
Exchange
NasdaqGM
Company URL
http://www.marinuspharma.com
Company Phone
484-801-4670
CEO
Christopher Michael Cashman
Headquarters
Pennsylvania
Business Address
170 N RADNOR CHESTER RD, SUITE 250, RADNOR, PA 19087
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001267813
About

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of neuropsychiatric therapeutics. Its clinical stage drug candidate, ganaxolone, is a novel synthetic small molecule that is an analog of allopregnanolone, a natural occurring neurosteriod produced by the human body, which modulates gamma-aminobutyric acid a neurotransmitter in the brain. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Description

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading